SITAGLIPTINE/METFORMINE ZENTIVA K.S 50 mg/1000 mg, film-coated tablet 60 tablets
Active ingredients: Metformin hydrochloride, Sitagliptin phosphate hydrate, Sitagliptin
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet60 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- SITAGLIPTINE/METFORMINE ZENTIVA K.S 50 mg/1000 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquettes PVC PVDC aluminium de 60 comprimés
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 18 Jul 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66388233CIP73030091CIP133400930300916Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| SITAGLIPTINEcomprimé | 50 mg · un comprimé | FT |
| PHOSPHATE DE SITAGLIPTINE MONOHYDRATÉcomprimé | — | SA |
| CHLORHYDRATE DE METFORMINEcomprimé | 1000 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.